Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

3

Investigational

2

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Calcitonin gene-related peptide type 1 receptor

2

voltage-gated potassium channel activity

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

Phase III

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

5

2018

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Lambert-Eaton myasthenic syndrome

2

Migraine

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Assistance Publique Hopitaux de Paris

2

Merck

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

EPA CompTox

7

FDA UNII

7

PUBCHEM

7

MERCK INDEX

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

OTHER NERVOUS SYSTEM DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER NERVOUS SYSTEM DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other nervous system drugs

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

4

Salts, Hydrates, Esters, etc.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

AMIFAMPRIDINE

RU4S6E2G0J

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2018

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

voltage-gated potassium channel activity

Conditions:

Lambert-Eaton myasthenic syndrome

Amifampridine (Firdapse), currently approved in the European Union, is the first and only approved drug for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, a rare autoimmune disease with the primary symptoms of muscle...

weakness. In LEMS, the body’s own immune system attacks connections between nerves and muscles and disrupts the ability of nerve cells to send signals to muscle cells. Amifampridine blocks voltage-dependent potassium channels, thereby prolonging pre-synaptic cell membrane depolarization. Prolonging the action potential enhances the transport of calcium into the nerve ending. The resulting increase in intracellular calcium concentrations facilitates exocytosis of acetylcholine containing vesicles, which in turn enhances neuromuscular transmission. Amifampridine phosphate has been granted Orphan Drug Designation and Breakthrough Therapy designation by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).

TELCAGEPANT

D42O649ALL

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Calcitonin gene-related peptide type 1 receptor

Conditions:

Telcagepant (MK-0974) is a calcitonin gene-related peptide receptor antagonist. Merck & Co was developing telcagepant for the treatment of pain. Telcagepant is an extremely potent CGRP antagonist with a Ki = 0.77 (0.07 nM). Telcagepant showed eff...

icacy against acute migraines; however, different patient populations may show more beneficial effects with telcagepant versus triptans. In the acute treatment of migraine, Telcagepant was found to have equal potency to rizatriptan and zolmitriptan in two Phase III clinical trials. Merck & Co has now terminated development of the drug.

2,3-DIAMINO-6-METHOXYPYRIDINE

VGV76K138F

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

2,3-DIBROMOPROPENE

8DNE7K7Z6P

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

AMIFAMPRIDINE PHOSPHATE

8HF8FIN815

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2018

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

voltage-gated potassium channel activity

Conditions:

Lambert-Eaton myasthenic syndrome

Amifampridine (Firdapse), currently approved in the European Union, is the first and only approved drug for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, a rare autoimmune disease with the primary symptoms of muscle...

weakness. In LEMS, the body’s own immune system attacks connections between nerves and muscles and disrupts the ability of nerve cells to send signals to muscle cells. Amifampridine blocks voltage-dependent potassium channels, thereby prolonging pre-synaptic cell membrane depolarization. Prolonging the action potential enhances the transport of calcium into the nerve ending. The resulting increase in intracellular calcium concentrations facilitates exocytosis of acetylcholine containing vesicles, which in turn enhances neuromuscular transmission. Amifampridine phosphate has been granted Orphan Drug Designation and Breakthrough Therapy designation by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).

TELCAGEPANT POTASSIUM

L303VER2NG

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Calcitonin gene-related peptide type 1 receptor

Conditions:

Telcagepant (MK-0974) is a calcitonin gene-related peptide receptor antagonist. Merck & Co was developing telcagepant for the treatment of pain. Telcagepant is an extremely potent CGRP antagonist with a Ki = 0.77 (0.07 nM). Telcagepant showed eff...

icacy against acute migraines; however, different patient populations may show more beneficial effects with telcagepant versus triptans. In the acute treatment of migraine, Telcagepant was found to have equal potency to rizatriptan and zolmitriptan in two Phase III clinical trials. Merck & Co has now terminated development of the drug.

2,3-DIAMINO-6-METHOXYPYRIDINE DIHYDROCHLORIDE

I60KKO0GSO

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1